Logo

Vivesto Reports Approval of the US Clinical Paccal Vet Study in Dogs with Splenic Hemangiosarcoma

Share this

Vivesto Reports Approval of the US Clinical Paccal Vet Study in Dogs with Splenic Hemangiosarcoma

Shots:

  • The US Veterinary Review Board Clinical Studies Committee has approved the company’s Paccal Vet clinical trial in dogs with splenic hemangiosarcoma following splenectomy
  • The study will investigate Paccal Vet in dogs with various stages of splenic hemangiosarcoma (HSA) post-splenectomy. It comprises 4 treatment cycles and involves 2 cohorts, each with a maximum of 23 patients. Conducted at 6 clinical sites in Washington and Oregon, the first dosing is anticipated in early 2024, with a planned interim analysis in the H2’24
  • Paccal Vet incorporates paclitaxel, formulated using the company's XR-17 technology

Ref: Vivesto | Image: Vivesto

Related News:- Jaguar Health’s Canalevia-CA1 Receives Conditional Approval Renewal from the US FDA for Chemotherapy-Induced Diarrhea in Dogs

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions